Table 3.
Cox proportional hazards models of negative conversion time.
| Variables | All patients (N = 168) | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|---|
| Univariable HR (95%CI) | P | Multivariable HR(95%CI) | P | Multivariable HR(95%CI) | P | |||
| Gender | Female | 79 (47.0) | 1.00(Ref.) | |||||
| Male | 89 (53.0) | 0.94 (0.69–1.27) | 0.681 | NA | NA | NA | NA | |
| Age group, y | 0-6 | 78 (46.4) | 1.00(Ref.) | |||||
| >6, ≤12 | 61 (36.3) | 1.06 (0.76–1.48) | 0.738 | NA | NA | NA | NA | |
| >12, <18 | 29 (17.3) | 0.70 (0.45–1.09) | 0.117 | NA | NA | NA | NA | |
| Vaccinationb1 | Unvaccinated | 50 (31.2) | 1.00(Ref.) | |||||
| Vaccinated | 110 (68.8) | 1.06 (0.76–1.48) | 0.735 | NA | NA | NA | NA | |
| Tertiles of IgG | T1(0.01–0.42 S/CO) | 56 (33.3) | 1.00(Ref.) | |||||
| T2(0.43–3.43 S/CO) | 56 (33.3) | 1.04 (0.72–1.51) | 0.840 | NA | NA | NA | NA | |
| T3(3.44–134.32 S/CO) | 56 (33.4) | 1.46 (1.00–2.12) | 0.050 | NA | NA | NA | NA | |
| CRP levels | No. | 165 | ||||||
| ≤10 mg/L | 151 (91.5) | 1.00(Ref.) | ||||||
| 11–19 mg/L | 7 (4.2) | 0.60 (0.28–1.28) | 0.186 | NA | NA | NA | NA | |
| ≥20 mg/L | 7 (4.2) | 1.27 (0.593–2.72) | 0.539 | NA | NA | NA | NA | |
| PCT levels | No. | 155 | ||||||
| <0.1 ng/ml | 105 (67.7) | 1.00(Ref.) | ||||||
| 0.1–0.25 ng/ml | 30 (19.4) | 0.61 (0.14–2.76) | 0.524 | NA | NA | NA | NA | |
| >0.25 ng/ml | 20 (12.9) | 0.92 (0.20–4.14) | 0.912 | NA | NA | NA | NA | |
| SAA levels | No. | 156 | ||||||
| ≤10 μg/ml | 2 (1.3) | 1.00(Ref.) | ||||||
| >10 μg/ml | 154 (98.7) | 0.51 (0.12–2.08) | 0.350 | NA | NA | NA | NA | |
| IL-6 levels | No. | 156 | ||||||
| ≤7 pg./ml | 121 (77.6) | 1.00(Ref.) | ||||||
| >7 pg./ml | 35 (22.4) | 1.04 (0.71–1.51) | 0.854 | NA | NA | NA | NA | |
| ALT levels | No. | 167 | ||||||
| ≤40 U/L | 149 (89.2) | 1.00(Ref.) | ||||||
| 41-59 U/L | 11 (6.6) | 0.86 (0.46–1.58) | 0.621 | NA | NA | NA | NA | |
| ≥60 U/L | 7 (4.2) | 0.77 (0.36–1.64) | 0.493 | NA | NA | NA | NA | |
| AST levels | No. | 168 | ||||||
| ≤40 U/L | 132 (78.6) | 1.00(Ref.) | ||||||
| 41–59 U/L | 21 (12.5) | 0.87 (0.55–1.39) | 0.564 | NA | NA | NA | NA | |
| ≥60 U/L | 15 (8.9) | 0.84 (0.49–1.43) | 0.515 | NA | NA | NA | NA | |
| DDi levels | No. | 158 | ||||||
| ≤0.50 μg/ml | 121 (76.6) | 1.00(Ref.) | ||||||
| 0.51–0.99 μg/ml | 26 (16.5) | 1.08 (0.71–1.66) | 0.716 | NA | NA | NA | NA | |
| ≥1.00 μg/ml | 11 (7.0) | 1.05 (0.57–1.96) | 0.873 | NA | NA | NA | NA | |
| WBC | No. | 167 | ||||||
| Mean (SD), 10^9/L | 6.1 (2.4) | 1.00 (0.94–1.06) | 0.955 | NA | NA | NA | NA | |
| NEUT | No. | 167 | ||||||
| Mean (SD), 10^9/L | 3.0 (1.7) | 1.00 (0.91–1.10) | 0.987 | NA | NA | NA | NA | |
| LYM | No. | 167 | ||||||
| Mean (SD), 10^9/L | 2.4 (1.8) | 0.99 (0.92–1.07) | 0.785 | NA | NA | NA | NA | |
| Hb | No. | 167 | ||||||
| Mean (SD), g/L | 131.1 (11.5) | 1.00 (0.99–1.01) | 0.969 | NA | NA | NA | NA | |
| PLT | No. | 167 | ||||||
| Mean (SD),10^9/L | 238.5 (70.7) | 1.001 (0.999–1.004) | 0.177 | NA | NA | NA | NA | |
| FIB | No. | 163 | ||||||
| Mean (SD), g/L | 2.3 (0.6) | 0.92 (0.70–1.21) | 0.547 | NA | NA | NA | NA | |
| N-CT | No. | 155 | ||||||
| Mean (SD) | 27.6 (4.8) | 1.05 (1.02–1.08) | 0.004 | NA | NA | NA | NA | |
| ORF1ab-CT | No. | 151 | ||||||
| Mean (SD) | 27.3 (5.4) | 1.04 (1.01–1.07) | 0.007 | 1.04 (1.01–1.07) | 0.007 | 1.04 (1.01–1.07) | 0.014 | |
| CK | No. | 166 | ||||||
| Mean (SD), U/L | 98.0 (41.8) | 0.998 (0.994–1.002) | 0.367 | NA | NA | NA | NA | |
| CK-MB | No. | 166 | ||||||
| Mean (SD), U/L | 19.6 (8.9) | 0.999 (0.980–1.019) | 0.940 | NA | NA | NA | NA | |
| LDH | No. | 167 | ||||||
| Mean (SD), U/L | 258.0 (67.5) | 0.999 (0.997–1.002) | 0.666 | NA | NA | NA | NA | |
| SARS-CoV-2 IgM | No. | 168 | ||||||
| Median (IQR), S/CO | 0.14 (0.07, 0.30) | 1.32 (1.01–1.73) | 0.042 | NA | NA | NA | NA | |
Model 2, the multivariate regression of IgG tertiles and time to negative conversion adjusted for age, gender, N-CT, ORF1ab-CT, SARS-CoV-2 IgM, and PLT. Model 3, multivariate regression of IgG tertiles and time to negative conversion adjusted for age, gender, N-CT, ORF1ab-CT, PLT, SARS-CoV-2 IgM, PLT, vaccination, and LYM. b1, the vaccine status of the 8 patients was missing. Missing data were not included in both univariate and multivariate regression.